Gillmore Staging (ATTR Amyloidosis) Calculator
- Gillmore Staging (ATTR Amyloidosis): Explanation and Clinical Context
Gillmore staging is a validated system to stratify prognosis in patients with transthyretin (ATTR) cardiac amyloidosis, using serum NT-proBNP and renal function (eGFR) as key predictors.
Stage 1 corresponds to NT-proBNP < 3000 ng/L and eGFR > 45 mL/min/1.73m², indicating the lowest risk group.
Stage 2 includes patients who meet only one of the above criteria (either NT-proBNP > 3000 ng/L or eGFR < 45 mL/min/1.73m²), representing intermediate risk.
Stage 3 applies to patients with both NT-proBNP > 3000 ng/L and eGFR < 45 mL/min/1.73m², representing the highest risk group.
This tool helps clinicians with risk stratification, management decisions, and prognostication for ATTR cardiac amyloidosis.
Reference:
Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799–2806. doi:10.1093/eurheartj/ehy219
Discussion
No discussions yet. Be the first to comment.
Create Note
Notes are stored privately on your device only. No login required. Nothing is uploaded or shared.